Skip to main content
OpenTrials

Clinical trial condition

Anatomic Stage III Breast Cancer AJCC v8

Explore clinical trials studying Anatomic Stage III Breast Cancer AJCC v8. Study availability and eligibility vary by location and protocol.

122 public trials 43 recruiting studies
Refine in advanced search Browse all conditions

Anatomic Stage III Breast Cancer AJCC v8 trial results

Recruiting

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

NCT06058377

Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, +1 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Katmai Oncology Group Anchorage, Alaska, United States
  • University of Arizona Cancer Center-Orange Grove Campus Tucson, Arizona, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
View all 556 locations
View Trial Details
Recruiting

Time Restricted Eating for the Improvement of Outcomes in Patients With Stage I-III Breast Cancer Receiving Chemotherapy Before Surgery

NCT05327608

Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, +1 more
Locations
  • Jefferson Cherry Hill Hospital Cherry Hill, New Jersey, United States
  • Sidney Kimmel Cancer Center Washington Township, , NJ USA Sewell, New Jersey, United States
  • Thomas Jefferson University Hospital Philadelphia, Pennsylvania, United States
  • Jefferson Torresdale Hospital Philadelphia, Pennsylvania, United States
View Trial Details
Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

NCT05564377

Conditions
Adnexal Diseases, Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, +36 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • CTCA at Western Regional Medical Center Goodyear, Arizona, United States
View all 482 locations
View Trial Details
Recruiting

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

NCT05422794

Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Diseases, +9 more
Locations
  • Boston Medical Center Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • NYU Langone Hospital - Long Island Mineola, New York, United States
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, United States
View Trial Details
Recruiting

A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer

NCT07741968

Conditions
Adnexal Diseases, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, +44 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • City of Hope at Irvine Lennar Irvine, California, United States
  • City of Hope at Arcadia Arcadia, California, United States
  • City of Hope at Seacliff Huntington Beach, California, United States
View Trial Details

Related conditions